Medical
What is CBDV and what does it do?
Answer
CBDV (Cannabidivarin) is a non-psychoactive cannabinoid found in cannabis plants, structurally similar to CBD but with a shorter side chain. First isolated in 1969, CBDV is typically found in higher concentrations in indica-dominant strains and certain landrace varieties from regions like Pakistan, India, and Mexico.
CBDV content in most cannabis strains ranges from 0.1% to 1%, though some specialized cultivars can contain up to 7% CBDV. The compound is most abundant in strains with higher CBD content and lower THC levels, making it particularly prevalent in hemp varieties and medicinal cannabis cultivars.
Preclinical research suggests CBDV may have several therapeutic properties. Studies indicate potential anticonvulsant effects, with pharmaceutical company GW Pharmaceuticals (now part of Jazz Pharmaceuticals) having conducted Phase II clinical trials for CBDV as a treatment for epilepsy, particularly Rett syndrome and focal seizures. The compound appears to interact with TRP channels and may modulate calcium signaling in neurons.
Additional research has explored CBDV's potential for autism spectrum disorders, with some studies showing promising results in animal models. The compound may also possess anti-inflammatory and neuroprotective properties, though human clinical data remains limited.
CBDV is produced through the same biosynthetic pathway as other cannabinoids, starting from olivetolic acid and geranyl pyrophosphate. The compound can be extracted and isolated using similar methods as CBD, including CO2 extraction and chromatographic purification.
The global CBDV market is emerging as pharmaceutical companies and cannabis producers recognize its potential. Several licensed producers are developing CBDV-enriched strains for medical applications.
**Disclaimer:** This information is for educational purposes only and should not be considered medical advice. Consult healthcare professionals before using cannabis products for medical purposes. CBDV research is ongoing, and therapeutic claims require further clinical validation.